Physician profile
Patrick Albrant
NPI 1669081287
$1,099.95
in general payments reported to CMS, 2019-2025
25 companies · $1,100 in 2025
The $1,100 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,099.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $153.42 | 2025 | Fintepla, Briviact, Rystiggo |
| Abbvie INC. | $131.36 | 2025 | |
| Jazz Pharmaceuticals INC. | $86.33 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $75.97 | 2025 | Lumryz |
| Tg Therapeutics, INC. | $60.31 | 2025 | |
| Pfizer INC. | $50.47 | 2025 | |
| Ani Pharmaceuticals, INC. | $50.42 | 2025 | Purified Cortrophin Gel |
| Biogen, INC. | $38.99 | 2025 | Skyclarys |
| Argenx US, INC. | $38.06 | 2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $38.06 | 2025 | Rexulti |
| Janssen Biotech, INC. | $38.01 | 2025 | |
| Vanda Pharmaceuticals INC. | $36.49 | 2025 | Ponvory |
| Csl Behring | $31.16 | 2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $28.89 | 2025 | Hyqvia |
| Neurocrine Biosciences, INC. | $28.59 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $26.85 | 2025 | |
| Lundbeck LLC | $26.71 | 2025 | Vyepti |
| Merz Pharmaceuticals, LLC | $25.11 | 2025 | Xeomin |
| Alnylam Pharmaceuticals INC. | $24.87 | 2025 | Givlaari |
| Emd Serono, INC. | $22.45 | 2025 | |
| Axsome Therapeutics, INC. | $21.35 | 2025 | Symbravo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.16 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $17.90 | 2025 | Daybue |
| Hospira, INC. | $16.27 | 2025 | |
| Genentech USA, INC. | $13.75 | 2025 | Ocrevus Zunovo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Albrant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.